Article
Chemistry, Multidisciplinary
Hafiza Rida Farooq Chudhary, Amjad Ali, Sadia Bibi, Muhammad Waqas, Shazia Rafique, Muhammad Idrees, Sobia Ahsan Halim, Magda H. Abdellattif, Ajmal Khan, Ahmed Al-Harrasi
Summary: HCV is a global public health problem with a high number of infections worldwide. It is a leading cause of liver cancer due to the frequent occurrence of HCV infection, especially in those with HCV cirrhosis. This study analyzed the transcriptional analysis of the TP53 gene in HCV-infected patients treated with different antiviral therapies. The results showed that TP53 expression was significantly upregulated in patients with virological responses and HCC, and sofosbuvir + daclatasvir treatment had a significant impact on TP53 expression.
Article
Virology
Ahmed M. Mostafa, Hesham A. Saafan, Ahmed S. Al-Tawashi, Muhannad H. Kasem, Ahmed M. Alaa, Mahmoud M. Eltobgy, Ahmed S. Moubarak, Manar M. Gharib, Mohamed A. Awwad, Hazem M. Omar, Marwa O. El-Derany
Summary: This study aimed to investigate the association between haplotypes in IL-17A receptor rs2275913 and rs3819024 and development of HCC in CHC patients treated with either triple therapy or with dual therapy. The results showed that the presence of G-G haplotype in IL-17A was inversely associated with HCC development in patients receiving triple therapy. High serum AFP levels were directly associated with HCC development in patients receiving triple therapy.
Article
Pediatrics
Magdalena Pluta, Maria Pokorska-Spiewak, Malgorzata Aniszewska, Zbigniew Lewandowski, Barbara Kowalik-Mikolajewska, Magdalena Marczynska
Summary: This study evaluated the influence of host and viral factors on the response to PEG-IFN+RBV therapy in children with chronic hepatitis C. The results showed a significant relationship between virus genotype and early virologic response. Detecting favorable HCV and IL28B genotype prior to commencing therapy and continuing treatment based on early virologic response is of major importance for children in whom DAA treatment is currently not available.
MINERVA PEDIATRICS
(2022)
Article
Virology
Chia-Min Wu, Fu-Hsiung Su, Chih-Hsin Muo, Jou-Chen Huang, Meei-Maan Wu, Chih-Ching Yeh
Summary: This study found that patients with HCV infection treated with PegIFN/RBV therapy had a significantly increased risk of retinopathy, particularly retinal hemorrhage.
Article
Immunology
Mina S. Farag, Margo J. H. van Campenhout, Maria Pfefferkorn, Janett Fischer, Danilo Deichsel, Andre Boonstra, Anneke J. van Vuuren, Peter Ferenci, Jordan J. Feld, Thomas Berg, Bettina E. Hansen, Florian van Bommel, Harry L. A. Janssen
Summary: During PEG-IFN treatment for HBeAg-negative CHB, HBV-RNA showed a rapid and significant decrease that correlated with treatment response and HBsAg loss at long-term follow-up.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Virology
Kamil Grubczak, Anna Grzeszczuk, Monika Groth, Anna Hryniewicz, Anna Kretowska-Grunwald, Robert Flisiak, Marcin Moniuszko
Summary: HIV/HCV coinfection increases the burden of HCV infection and accelerates disease progression, while regulatory T cells play a crucial role in antiviral immune response during viral treatment.
Review
Virology
Yi-Wen Huang, Albert Qin, Chan-Yen Tsai, Pei-Jer Chen
Summary: Ropeginterferon alfa-2b is a promising treatment option for MPN and chronic viral hepatitis due to its favorable pharmacokinetic profile and demonstrated efficacy in clinical studies. Administered once every two weeks, it has shown to be well-tolerated and effective in treating chronic hepatitis B, C, and D.
Letter
Immunology
Emmanouil Papasavvas, Livio Azzoni, Brian N. Ross, Matthew Fair, Bonnie J. Howell, Daria J. Hazuda, Karam Mounzer, Jay R. Kostman, Pablo Tebas, Luis J. Montaner
Summary: The post-hoc analysis of three clinical studies involving chronically HIV-infected, immune-reconstituted individuals showed that both Peg-IFN-alpha 2b and Peg-IFN-alpha 2a immunotherapies had similar rates of viral suppression during a 4-week ART interruption, despite the latter maintaining significantly higher trough blood levels.
Article
Genetics & Heredity
Koji Fujita, Hironori Nishitsuji, Hisakazu Iwama, Tomoko Tadokoro, Asahiro Morishita, Shima Mimura, Masafumi Ono, Takashi Himoto, Kunitada Shimotohno, Tsutomu Masaki
Summary: This study aimed to investigate whether miR-6126 down-regulated the expression level of sodium taurocholate cotransporting polypeptide (NTCP), a host cell receptor required for HBV entry. HepG2-NTCP cells were transfected with miR-6126 to evaluate the expression level of NTCP and the attachment of PreS1 to NTCP. The results showed that miR-6126 transfection decreased the expression level of NTCP, reduced the attachment of PreS1 to HepG2-NTCP cells and PXB cells, and decreased the HBs antigen level in the culture supernatant. The stability of NTCP mRNA was also reduced by miR-6126 transfection in HepG2 cells. Overall, miR-6126 downregulated NTCP expression, leading to the inhibition of HBV entry into hepatocytes.
Article
Microbiology
Wen-Xin Wang, Rui Jia, Jin-Wen Song, Xiaoning Zhang, Shuang-Nan Zhou, Fu-Sheng Wang, Junliang Fu
Summary: This study investigated the effect of different antiviral agents on the immunogenicity of SARS-CoV-2 vaccines in patients with chronic hepatitis B. It was found that Peg-interferon-alpha therapy could maintain the immunogenicity and was associated with high levels of IFN-gamma. A booster dose effectively recalled the immunogenicity of the vaccines.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Pharmacology & Pharmacy
Ming-Han Hsieh, Tzu-Yu Kao, Ting-Hui Hsieh, Chun-Chi Kao, Cheng-Yuan Peng, Hsueh-Chou Lai, Po-Heng Chuang, Jung-Ta Kao
Summary: SVR lowers the risk of liver histological progression but does not guarantee fibrosis clearance. For SVR cases, those with baseline F >= 2 or without significantly declined follow-up AST levels should be specifically monitored. As for non-SVR cases, those with a higher baseline AST or glucose level should preferentially receive retreatment.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2022)
Article
Medicine, General & Internal
Nevine Bishai, Walid El Nabawy, Mohamed El Fiki, Mohamed Ibrahim, Nouman El Garem
Summary: This study compared the effectiveness of different treatment regimens for chronic HCV patients and found that the regimen using sofosbuvir, daclatasvir, and ribavirin showed the highest cure rate with the least side effects.
IRISH JOURNAL OF MEDICAL SCIENCE
(2023)
Article
Multidisciplinary Sciences
Yoko Yamagiwa, Keitaro Tanaka, Keitaro Matsuo, Keiko Wada, Yingsong Lin, Yumi Sugawara, Tetsuya Mizoue, Norie Sawada, Hidemi Takimoto, Hidemi Ito, Tetsuhisa Kitamura, Ritsu Sakata, Takashi Kimura, Shiori Tanaka, Manami Inoue
Summary: Antiviral therapy for chronic hepatitis C reduces the risk of hepatocellular carcinoma (HCC) occurrence in Japanese patients.
SCIENTIFIC REPORTS
(2023)
Article
Virology
Mengqi Luo, Lingyan Zhang, Chou Yang, Bin Zhou, Jinlin Hou, De-Ke Jiang
Summary: This study found that single-nucleotide polymorphism CXCL13_rs76084459 is significantly associated with response to PegIFNa therapy in patients with chronic hepatitis B. Furthermore, a polygenic score composed of 6 SNPs including CXCL13_rs76084459 has a better predictive value for PegIFNa treatment response.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Medicine, Research & Experimental
Jennifer J. Lin, Catrina M. Loucks, Jessica N. Trueman, Britt Drogemoller, Galen E. B. Wright, Eric M. Yoshida, Jo-Ann Ford, Samuel S. Lee, Richard B. Kim, Bandar Al-Judaibi, Ute Schwarz, Alnoor Ramji, Edward Tam, Colin J. Ross, Bruce C. Carleton
Summary: A novel genetic variant in the glycophorin C gene was identified to provide protection against ribavirin-induced anemia. Additionally, genetic variants in ITPA and VDR genes were confirmed to be important predictors of this adverse reaction.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Oncology
Luigi Bolondi, Antonio Craxi, Franco Trevisani, Bruno Daniele, Giovan Giuseppe Di Costanzo, Stefano Fagiuoli, Calogero Camma, Paolo Bruzzi, Romano Danesi, Federico Spandonaro, Corrado Boni, Armando Santoro, Massimo Colombo
Article
Gastroenterology & Hepatology
Paola Dongiovanni, Salvatore Petta, Cristina Maglio, Anna Ludovica Fracanzani, Rosaria Pipitone, Enrico Mozzi, Benedetta Maria Motta, Dorota Kaminska, Raffaela Rametta, Stefania Grimaudo, Serena Pelusi, Tiziana Montalcini, Anna Alisi, Marco Maggioni, Vesa Karja, Jan Boren, Pirjo Kakela, Vito Di Marco, Chao Xing, Valerio Nobili, Bruno Dallapiccola, Antonio Craxi, Jussi Pihlajamaki, Silvia Fargion, Lars Sjostrom, Lena M. Carlsson, Stefano Romeo, Luca Valenti
Article
Gastroenterology & Hepatology
Salvatore Petta, Marcello Maida, Stefania Grimaudo, Rosaria M. Pipitone, Fabio S. Macaluso, Daniela Cabibi, Calogero Camma, Vito Di Marco, Sandro Sferrazza, Antonio Craxi
LIVER INTERNATIONAL
(2016)
Review
Gastroenterology & Hepatology
Giuseppe Cabibbo, Ciro Celsa, Calogero Camma, Antonio Craxi
LIVER INTERNATIONAL
(2018)
Article
Gastroenterology & Hepatology
Salvatore Petta, Ester Vanni, Elisabetta Bugianesi, Vito Di Marco, Calogero Camma, Daniela Cabibi, Lavinia Mezzabotta, Antonio Craxi
LIVER INTERNATIONAL
(2015)
Article
Gastroenterology & Hepatology
Elena Buzzetti, Salvatore Petta, Roberta Manuguerra, Tu Vinh Luong, Daniela Cabibi, Elena Corradini, Antonio Craxi, Massimo Pinzani, Emmanuel Tsochatzis, Antonello Pietrangelo
LIVER INTERNATIONAL
(2019)
Article
Gastroenterology & Hepatology
Loreta A. Kondili, Ivane Gamkrelidze, Sarah Blach, Andrea Marcellusi, Massimo Galli, Salvatore Petta, Massimo Puoti, Stefano Vella, Homie Razavi, Antonio Craxi, Francesco S. Mennini
LIVER INTERNATIONAL
(2020)
Review
Gastroenterology & Hepatology
Domenico Alvaro, Guido Carpino, Antonio Craxi, Annarosa Floreani, Antonio Moschetta, Pietro Invernizzi
LIVER INTERNATIONAL
(2020)
Review
Gastroenterology & Hepatology
Giuseppe Cabibbo, Giacomo Emanuele Maria Rizzo, Caterina Stornello, Antonio Craxi
Summary: SARS-CoV-2 infection may result in liver cell damage, particularly with more significant impact on patients with cirrhosis, and the specific mechanism of injury is still unclear. International societies have outlined specific interventions for high-risk populations, along with recommendations for treatment and follow-up during the COVID-19 pandemic.
JOURNAL OF VIRAL HEPATITIS
(2021)
Review
Gastroenterology & Hepatology
Loreta A. Kondili, Antonio Craxi, Alessio Aghemo
Summary: Many high-income countries may find it challenging to achieve the WHO targets for eliminating HCV by 2030, with key factors for progress including identifying and treating the majority of infected individuals. Evaluating the cost-effectiveness and sustainability of different HCV screening and treatment strategies based on specific country and population contexts is essential to support evidence-based policy for HCV elimination.
LIVER INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Francesco S. Mennini, Andrea Marcellusi, Sarah Robbins Scott, Simona Montilla, Antonio Craxi, Maria Buti, Liana Gheorghe, Stephen Ryder, Loreta A. Kondili
Summary: This study assessed the clinical and economic impact of DAA therapy for HCV in England, Italy, Romania, and Spain, finding significant cost-savings and a short break-even point. A treatment delay due to COVID-19 may increase liver mortality in all countries.
LIVER INTERNATIONAL
(2021)
Article
Infectious Diseases
Loreta A. Kondili, Massimo Andreoni, Alfredo Alberti, Salvatore Lobello, Sergio Babudieri, Antonio Saverio Roscini, Rocco Merolla, Walter Marrocco, Antonio Craxi
Summary: This study utilized a probabilistic modelling approach to estimate the number of untreated HCV-infected individuals in Italy, revealing that over 280,000 individuals may be undiagnosed or unlinked to care, with significant heterogeneity across major transmission routes.
Article
Gastroenterology & Hepatology
Andrea Marcellusi, Francesco Saverio Mennini, Murad Ruf, Claudio Galli, Alessio Aghemo, Maurizia R. Brunetto, Sergio Babudieri, Antonio Craxi, Massimo Andreoni, Loreta A. Kondili
Summary: By simulating a Markov disease progression model, we evaluated the cost effectiveness and sustainability of different algorithms for HCV active infection diagnosis in a high endemic country. The results showed that HCV-RNA reflex testing is the most cost-effective diagnostic option.
LIVER INTERNATIONAL
(2022)
Article
Gastroenterology & Hepatology
Maria Buti, Antonio Craxi, Graham R. Foster, Mojca Maticic, Francesco Negro, Stefan Zeuzem, Fabien Zoulim
Summary: This study focuses on the elimination of chronic viral hepatitis and explores the issues of goal setting and measurement.
JOURNAL OF HEPATOLOGY
(2022)
Letter
Gastroenterology & Hepatology
Loreta A. Kondili, Maria Grazia Rumi, Antonio Craxi
JOURNAL OF HEPATOLOGY
(2023)